Skip to main content

ALX Oncology Holdings, Inc. (ALXO)

NASDAQ: ALXO · IEX Real-Time Price · USD
74.98 -3.80 (-4.82%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap3.02B
Revenue (ttm)n/a
Net Income (ttm)-59.99M
Shares Out40.34M
EPS (ttm)-1.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume75,632
Open77.85
Previous Close78.78
Day's Range74.96 - 79.00
52-Week Range32.51 - 117.45
Betan/a
AnalystsStrong Buy
Price Target97.29 (+29.8%)
Est. Earnings DateNov 11, 2021

About ALXO

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma...

IndustryBiotechnology
IPO DateJul 17, 2020
Employees29
Stock ExchangeNASDAQ
Ticker SymbolALXO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for ALXO stock is "Strong Buy." The 12-month stock price forecast is 97.29, which is an increase of 29.75% from the latest price.

Price Target
$97.29
(29.75% upside)
Analyst Consensus: Strong Buy

News

ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent an...

-- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center -- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center

1 week ago - GlobeNewsWire

ALX Oncology Announces Upcoming Virtual Investor Conference Participation

BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 check...

2 weeks ago - GlobeNewsWire

The 3 Best Biotech Stocks to Buy Right Now

Let your portfolio reflect your personality.

Other symbols:BEAMVRTX
1 month ago - The Motley Fool

So What's Going On With ALX Oncology's Stock?

ALX Oncology Holdings Inc (NASDAQ: ALXO) shares are trading higher by 19.3% at $74.69, potentially in sympathy with Trillium Therapeutics which announced an acquisition by Pfizer Monday. ALX Oncology is...

1 month ago - Benzinga

ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

BURLINGAME, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkp...

1 month ago - GlobeNewsWire

ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pemb...

The second of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated The second of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated

1 month ago - GlobeNewsWire

ALX Oncology Holdings Inc. (ALXO) Upgraded to Buy: Here's What You Should Know

ALX Oncology Holdings Inc. (ALXO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

ALX Oncology (ALXO) Sees Hammer Chart Pattern: Time to Buy?

ALX Oncology (ALXO) has been struggling lately, but the selling pressure may be coming to an end soon.

2 months ago - Zacks Investment Research

Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today

Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the bigg...

Other symbols:ADXSODTPRVB
2 months ago - Benzinga

ALX Oncology Shares Jump As ALX148 Shows ORR of 72% In Patients With HER2 Positive Stomach Cancer

ALX Oncology Holdings Inc (NASDAQ: ALXO) announced updated data from its ongoing ASPEN-01 Phase 1b trial evaluating ALX148 in combination with trastuzumab and chemotherapy to treat gastric or gastroesop...

2 months ago - Benzinga

ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Pat...

-- ORR of 72% Observed in Patients with > 2L HER2 Positive Gastric or Gastroesophageal Junction Cancer  -- Estimated OS at 12 months of 76%  -- ALX Oncology to Host Conference Call on July 6 th at 8:30 ...

2 months ago - GlobeNewsWire

ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies

--Interim report completed by ALX for a standard ongoing non-clinical safety study

3 months ago - GlobeNewsWire

ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in...

Randomized Phase 2/3 Study is Planned Based on Promising Results from the ASPEN-01 Phase 1b Trial in Gastric Cancer Patients Randomized Phase 2/3 Study is Planned Based on Promising Results from the ASP...

3 months ago - GlobeNewsWire

ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

BURLINGAME, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpo...

4 months ago - GlobeNewsWire

ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pemb...

- The first of two distinct randomized Phase 2 studies in collaboration with Merck  has been initiated

4 months ago - GlobeNewsWire

Alx Oncology Holding Meets 80-Plus Relative Strength Rating Benchmark

Alx Oncology Holding sees its Relative Strength Rating enter the 80-plus level. The post Alx Oncology Holding Meets 80-Plus Relative Strength Rating Benchmark appeared first on Investor's Business Daily.

4 months ago - Investors Business Daily

ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer

Updated results will be presented from ASPEN-01, the ongoing Phase 1b Study of ALX148 in combination trastuzumab, ramucirumab and paclitaxel in patients with gastric or gastroesophageal junction cancer ...

5 months ago - GlobeNewsWire

ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148

BURLINGAME, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 chec...

5 months ago - GlobeNewsWire

Top Wall Street analysts bet on these stocks for long-term growth

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Alcon, Semtech, Upstart, and others.

Other symbols:ALCCURISMTCUPST
5 months ago - CNBC

ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operat...

BURLINGAME, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 check...

6 months ago - GlobeNewsWire

ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics

BURLINGAME, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 check...

6 months ago - GlobeNewsWire

Why Earnings Season Could Be Great for ALX Oncology (ALXO)

ALX Oncology (ALXO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

6 months ago - Zacks Investment Research

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021

BURLINGAME, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 check...

8 months ago - GlobeNewsWire

ALX Oncology: Targeting The CD47 Receptor For Cancers

ALXO is a South Korea origin oncology concern valued at $3 billion on just phase 1 data. They have just a single asset, a CD47 blocker with some special differences.

8 months ago - Seeking Alpha

ALX Oncology: All Their Eggs In The Proverbial Basket

ALX Oncology is developing a drug that encourages macrophages to "eat" targeted cancer cells. Since releasing an IPO in Summer 2020, their share price has more than tripled, despite only having a single...

8 months ago - Seeking Alpha